Niraparib vs stenoparib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ovarian Cancer
Shared mechanism: PARP1/2 · full Ovarian Cancer pipeline
Niraparib
Marketed by GlaxoSmithKline and partners
NCT02655016 · Phase 3 · active, not recruiting
Patients were randomly assigned to niraparib or a matching placebo, with patients, doctors and outcome assessors all blinded. Progression-free survival, read by a blinded independent central review, was significantly longer with niraparib (hazard ratio 0.62, p<0.0001). The protocol reports a power calculation for this endpoint and 733 patients were enrolled against a planned 620.
Next expected readout: December 2026 · NCT05335993 (registry estimate)
Reported efficacy
Progression Free Survival (Up to 34 months): Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) (met)
Result source: NCT02655016
stenoparib
Developed by Allarity Therapeutics, Inc. under a licence from Eisai
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT03878849 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ovarian Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
stenoparib: no structured comparison results are available for Ovarian Cancer.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Niraparib
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
Available safety results
Niraparib
| Dropout rate | n/a: no completion milestonePhase 1: Niraparib 300 mg + Pembro NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination show 5 more resultsn/a: no completion milestonePhase 1: Niraparib 200 mg + Pembro NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 OC: Niraparib 200 mg + Pem NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 OC: Niraparib 200mg + Pemb NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 TNBC: Niraparib 200 mg + P NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 TNBC: Niraparib 200mg + Pe NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Phase 1: Niraparib 300 mg + Pembro NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results—Phase 1: Niraparib 200 mg + Pembro NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 OC: Niraparib 200 mg + Pem NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 OC: Niraparib 200mg + Pemb NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 TNBC: Niraparib 200 mg + P NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 TNBC: Niraparib 200mg + Pe NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 57.1%Phase 1: Niraparib 300 mg + Pembro NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results85.7%Phase 1: Niraparib 200 mg + Pembro NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination 41.5%Phase 2 OC: Niraparib 200 mg + Pem NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 OC: Niraparib 200mg + Pemb NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination 43.6%Phase 2 TNBC: Niraparib 200 mg + P NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 TNBC: Niraparib 200mg + Pe NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | anaemia 71.4% dyspnoea 57.1% nausea 57.1% NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination show 3 more resultsanaemia 71.4% constipation 71.4% fatigue 57.1% NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination fatigue 60.4% nausea 60.4% constipation 52.8% NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination nausea 61.8% fatigue 54.5% anaemia 43.6% NCT02657889 · Phase 1/2 · registry result, not featured evidence · combination |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Niraparib's landscape · stenoparib's landscape